Life Sciences market research reports by Global Markets Direct

• Kaposi Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Kaposi Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kaposi Sarcoma - Drugs In Development, 2022, provides an overview of the Kaposi Sarcoma (Infectious ... Read More

• Osteonecrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Osteonecrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteonecrosis - Drugs In Development, 2022, provides an overview of the Osteonecrosis (Musculoskeleta ... Read More

• Chronic Lymphocytic Leukemia (CLL) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,500

  Chronic Lymphocytic Leukemia (CLL) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Drugs In Development, 2022, provides an ove ... Read More

• Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis (Gout) - Drugs In Development, 2022, provides an overview of the Gouty Arthr ... Read More

• Gliosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Gliosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Drugs In Development, 2022, provides an overview of the Gliosarcoma (Oncology) pipeline l ... Read More

• Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leuke ... Read More

• Gallbladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Gallbladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Drugs In Development, 2022, provides an overview of the Gallbladder Cancer ... Read More

• Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 3,500

  Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report 'Insulin Like Growth Factor I - Drugs In Development, 2022'; Insulin Like Grow ... Read More

• Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Drugs In Development 2022, provides an overview of the Non-Hodgkin Lymp ... Read More

• Ankylosing Spondylitis (Bekhterev's Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Ankylosing Spondylitis (Bekhterev's Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Drugs In Development, 2 ... Read More

• Psoriatic Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Psoriatic Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Drugs In Development, 2022, provides an overview of the Psoriatic Arthrit ... Read More

• Anaplastic Oligoastrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Anaplastic Oligoastrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Oligoastrocytoma - Drugs In Development, 2022, provides an overview of the A ... Read More

• Herpes Labialis (Oral Herpes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Herpes Labialis (Oral Herpes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Labialis (Oral Herpes) - Drugs In Development, 2022, provides an overview of t ... Read More

• Secondary (Hypogonadotropic) Hypogonadism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Secondary (Hypogonadotropic) Hypogonadism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Drugs In Development, 2022, p ... Read More

• Diabetic Foot Ulcers Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Diabetic Foot Ulcers Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2022, provides an overview of the Diabetic Foot U ... Read More

• Diabetic Retinopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,500

  Diabetic Retinopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Drugs In Development, 2022, provides an overview of the Diabetic Retino ... Read More

• Dermatomyositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Dermatomyositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Drugs In Development, 2022, provides an overview of the Dermatomyositis (Musculos ... Read More

• Chondrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Chondrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chondrosarcoma - Drugs In Development, 2022, provides an overview of the Chondrosarcoma (Oncology) p ... Read More

• Vaginal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Vaginal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Drugs In Development, 2022, provides an overview of the Vaginal Cancer (Oncology) p ... Read More

• Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 3,500

  Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Metabotropic glutamate receptor 3 is a G protein-coupled receptor encoded b ... Read More

• Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma - Drugs In Development, 2022, provides an overview of the Anaplastic ... Read More

• Ewing Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,000

  Ewing Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Drugs In Development, 2022, provides an overview of the Ewing Sarcoma (Oncology) pipe ... Read More

• Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 3,500

  Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or ... Read More

• Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 3,500

  Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 13 molecules. Out of which approximately ... Read More

• Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  Oct 31, 2022  |  Published by: Global Markets Direct  |  USD 2,500

  Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer - Drugs In Development, 2022, provides an overview of the Endometrial Cancer ... Read More

< prev 1 2 3 4 5 6 7 8 9 10 next >